RU-2026104908-A - A composition intended for use in the treatment and/or prevention of chronic musculoskeletal pain, including chronic low back pain, chronic non-specific low back pain, osteoarthritis or other chronic musculoskeletal pain syndromes, containing delta-9-tetrahydrocannabinol and terpenes

Inventors

• БААШ Бастиан
• ФИШЕР Клеменс

Assignees

• ВЕРТАНИКАЛ ГМБХ

Dates

Publication Date

20260508

Application Date

20240731

Priority Date

20230801

Claims (20)

1. 1. A composition intended for use in the treatment and/or prevention of chronic musculoskeletal pain, including chronic low back pain (CLBP), chronic non-specific low back pain (CNSLBP), osteoarthritis and/or other chronic musculoskeletal pain syndromes that affect (a) area(s) or system(s) of the body such as joints, tendons, ligaments, bones and/or muscles, comprising delta-9-tetrahydrocannabinol (THC), alpha-bisabolol, guaiol and beta-caryophyllene and at least one additional terpene selected from the group consisting of linalool, alpha-humulene, nerolidol, caryophyllene oxide, alpha-pinene, camphene, beta-pinene, beta-myrcene, limonene, eucalyptol, ocimene, gamma-terpinene, terpinolene, alpha-terpinene, para-cymene, isopulegol and geraniol.
2. 2. A composition for use according to claim 1, wherein delta-9-tetrahydrocannabinol (THC) and alpha-bisabolol are present in the composition in a ratio of about 100:1 to 450:1.
3. 3. A composition for use according to claim 1 or 2, wherein delta-9-tetrahydrocannabinol (THC) and guaiol are present in the composition in a ratio of about 50:1 to 250:1.
4. 4. A composition for use according to one of claims 1-3, wherein delta-9-tetrahydrocannabinol (THC) and beta-caryophyllene are present in the composition in a ratio of about 50:1 to 250:1.
5. 5. A composition intended for use according to one of paragraphs 1-4, where
6. (a) delta-9-tetrahydrocannabinol (THC) and linalool are present in the composition in a ratio of approximately 450:1 to 1400:1;
7. (b) THC and alpha-humulene are present in the composition in a ratio of approximately 300:1 to 725:1;
8. (c) TNS and nerolidol are present in the composition in a ratio of approximately 200:1 to 600:1;
9. (d) THC and caryophyllene oxide are present in the composition in a ratio of from about 1000:1 to 2150:1;
10. (d) THC and alpha-pinene are present in the composition in a ratio of from about 5850:1 to 16000:1;
11. (e) THC and camphene are present in the composition in a ratio of from about 7300:1 to 132950:1;
12. (g) THC and beta-pinene are present in the composition in a ratio of approximately 6475:1 to 23100:1;
13. (z) THC and beta-myrcene are present in the composition in a ratio of approximately 1950:1 to 6300:1;
14. (i) THC and limonene are present in the composition in a ratio of approximately 1650:1 to 5050:1;
15. (k) THC and eucalyptol are present in the composition in a ratio of approximately 5050:1 to 38650:1;
16. (l) THC and ocimene are present in the composition in a ratio of approximately 2500:1 to 44700:1;
17. (m) THC and gamma-terpinene are present in the composition in a ratio of approximately 4700:1 to 35750:1;
18. (n) THC and terpinolene are present in the composition in a ratio of approximately 5450:1 to 129850:1;
19. (o) THC and alpha-terpinene are present in the composition in a ratio of approximately 5150:1 to 58550:1;
20. (p) THC and para-cymene are present in the composition in a ratio of approximately 4700:1 to 56700:1;